In a national Dutch cohort RFA ± ER was effective and had remarkably low rates of dysplastic recurrence. Moreover, these data support more lenient follow-up intervals and question the value...
Read more© 2022 – Revista Gastroenterología
Revista Gastroenterología
Both first-line treatment with Nivolumab plus chemotherapy and Nivolumab plus Ipilimumab resulted in significantly longer overall survival than chemotherapy alone in a phase 3 trial.
Read more
The newly developed CRAFITY score, composed of C-reactive protein and alpha-fetoprotein, is associated with survival and radiological response in patients receiving immunotherapy for hepatocellular carcinoma. The score can be helpful...
Read more
A recent meta-analysis indicates that for the treatment of cirrhosis-associated portal vein thrombosis, the bleeding risk is comparable between DOAC and vitamin K antagonists. However, DOAC were associated with a...
Read more
A recent meta-analysis shows that almost 40% of patients with liver cirrhosis are sarcopenic. Sarcopenia significantly increases the risk of mortality in patients with cirrhosis. Thus, adequate nutrition and physical...
Read more
Antibody responses and functions against viral spike proteins were impaired in IBD patients treated with anti-TNFα as compared to other therapies or healthy controls in a prospective trial from Israel.
Read more
In CDI patients with symptom resolution after standard-of-care antibiotics, SER-109 for 3 days was superior to placebo in reducing the risk of recurrent CDI infection in a phase 3 trial....
Read more
Author: Prof. Dr. Christoph F. Dietrich ©Falk Foundation e.V., Freiburg. All rights reserved.
Read more
Apixaban was associated with a significantly lower risk of PPB and thromboembolism than warfarin, dabigatran and rivaroxaban, particularly in older patients with right-sided polyps.
Read more
Eight weeks of cannabidiol (CBD)-rich cannabis treatment induced significant clinical and quality-of-life improvement without significant changes in inflammatory parameters or endoscopic scores in a placebo-controlled trial with Crohn’s disease patients.
Read more